ASP Isotopes Plans Commercial Delivery of Multiple Stable Isotopes in Second Half of 2026

ASP Isotopes Inc. recently presented its expansion plans for isotope production, radiopharmaceuticals, and helium operations at Canaccord Genuity's 46th Annual Growth Conference. The company aims to begin commercial delivery of stable isotopes including silicon-28, carbon-14, and ytterbium-176 in the second half of 2026.

Victor Petkov, the company's Chief Commercial Officer, stated that ASP Isotopes is leveraging its proprietary enrichment technology to serve electronics, nuclear medicine, and nuclear fuel-related markets. Currently, the company operates three production facilities in Pretoria, South Africa, primarily producing silicon-28 for semiconductor applications, as well as carbon-14 and ytterbium-176 for nuclear medicine-related uses.

Regarding the isotope supply chain, Petkov noted that the global isotope supply chain is relatively fragile, with production of certain isotopes being highly concentrated. The company hopes to provide Western customers with alternative supply options through its own production capacity.

ASP Isotopes has publicly disclosed two types of enrichment technologies. Among them, the aerodynamic separation process employs fixed-wall centrifuges to enrich gaseous elements and can be applied to materials such as silicon, methane, and xenon. This process features a modular design that can be scaled according to plant requirements, with capital expenditures lower than those of traditional centrifuge systems. The other technology, quantum enrichment, is a laser-based process suitable for non-gaseous metals and other elements. According to the company's description, this technology first vaporizes metal feedstock, then excites target isotopes through laser energy, and finally collects the enriched material on a charged metal plate. It can be applied to materials such as uranium, lithium, ytterbium, and gadolinium.

Beyond its isotope business, ASP Isotopes' Renergen platform holds the Virginia Gas Project, which plans to produce helium and liquefied natural gas. Petkov stated that the first phase of helium production at the project is expected to commence by the end of September, with revenue recognition anticipated in 2026. The company noted that helium demand spans semiconductor manufacturing, MRI systems, fiber optics, and aerospace, with helium playing an important role in semiconductor manufacturing due to its thermal conductivity and inertness.

In radiopharmaceuticals, the company's PET Labs platform is South Africa's largest producer of fluorine-18 radionuclides. Petkov stated that this business produces radioisotopes for nuclear medicine and has remained profitable for many years. According to a previous shareholder letter, the company expects this business to generate approximately $14 million in revenue in fiscal year 2026. Recent growth has been driven primarily by investments in the Pretoria radiopharmacy, including the installation of cyclotrons and related equipment, as well as increased demand from new PET scanners added at hospitals.

ASP Isotopes recently also acquired radiopharmaceutical production sites in Florida and South Carolina in the United States. Petkov stated that these sites currently produce products for SPECT diagnostics, including technetium-related products. The company plans to continue investing in these sites and install cyclotrons for PET isotope production, while also evaluating other investment opportunities in the United States and Europe.

The company stated that its stable isotope and radiopharmaceutical businesses are forming a vertically integrated model. ASP Isotopes plans to enrich stable isotopes such as nickel and ytterbium for use as feedstock in producing radioisotopes at PET Labs, thereby reducing supply chain risks and improving economics compared to companies that procure feedstock externally.

Regarding production progress, Petkov acknowledged delays at the South African stable isotope facility, attributed to legacy engineering issues involving components such as valves, heat exchangers, and compressors. For silicon-28, the company is processing silane and observing enrichment results, but achieving final product grade still requires the full 48-stage system and approximately 200 auxiliary compressors to operate in tandem. The company expects the system to be fully operational by the end of the year. Carbon-14 production, meanwhile, has been constrained by supply and quality limitations of specialty feedstock provided by a Canadian partner.

As of March 2026, ASP Isotopes' balance sheet showed net assets of approximately $290 million. Petkov stated that the company's medium-term target is to achieve over $300 million in EBITDA by 2031, a target that excludes the nuclear energy business. Its subsidiary being spun off, Quantum Leap Energy, is focused on developing uranium conversion, enrichment, and reduction services, as well as lithium-6 and lithium-7 production technologies.